COHERENT INC
Healthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.23B | $1.43B | $1.90B | $1.72B | $857.4M |
| Operating income | −$98.2M | −$430.2M | $83.1M | $393.0M | $325.5M | $127.6M |
| Net income | −$106.8M | −$414.1M | $53.8M | $247.4M | $207.1M | $87.5M |
| Total assets | $1.89B | $1.83B | $2.08B | $2.26B | $2.34B | $1.16B |
| Total liabilities | — | — | — | — | — | — |
| Equity | $868.2M | $927.2M | $1.28B | $1.31B | $1.16B | $910.8M |
| EPS (diluted) | $-4.38 | $-17.18 | $2.22 | $9.95 | $8.36 | $3.58 |
| Shares out. | 24.7M | 24.4M | 24.2M | 24.4M | 24.8M | 24.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −6.6%
- Net margin
- −7.2%
- Return on equity
- −12.3%
- Return on assets
- −5.7%
- Return on capital (ROCE)
- −6.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $35.16
- Revenue growth (YoY)
- 21.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Accruals / assets
- −9.5%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2024-09A Study of CBP-1008 in Patients With Advanced Solid Tumor
- Phase 1Recruitingreadout ~2024-10A Study of CBP-1018 in Patients With Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Skaggs Stephen ADirector | Jul 1, 2022 | D | 14,518 | — |
| Vij SandeepDirector | Jul 1, 2022 | D | 10,518 | — |
| Mcmullen Michael R.Director | Jul 1, 2022 | D | 6,043 | — |
| Sobey Mark StewartOfficer — EVP & Chief Operating Officer | Jul 1, 2022 | D | 35,421 | — |
| Matthews Beverly KayDirector | Jul 1, 2022 | D | 4,504 | — |
| Flatley Jay TDirector | Jul 1, 2022 | D | 43,018 | — |
| Palatnik Kevin S.Officer — Chief Financial Officer | Jul 1, 2022 | D | 43,808 | — |
| Mattes Andreas WOfficer — President and CEO | Jul 1, 2022 | D | 34,021 | — |
| Rogerson Garry WDirector | Jul 1, 2022 | D | 17,518 | — |
| Fletcher PamelaDirector | Jul 1, 2022 | D | 4,594 | — |
| Dimarco BretOfficer — Exec VP & Chief Legal Officer | Jul 1, 2022 | D | 39,827 | — |
| Palatnik Kevin S.Officer — Chief Financial Officer | Apr 29, 2022 | Grant | 97 | $218.20 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJul 1, 2022
- Other material eventJun 28, 2022
- Results of operationsMay 11, 2022
- Other material eventMay 3, 2022
- Director / officer changeMar 18, 2022
- Results of operationsFeb 9, 2022
- Results of operationsNov 9, 2021
- Other material eventAug 26, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GJul 11, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- 4OWNERSHIP DOCUMENTJul 1, 2022
- S-8 POSJul 1, 2022
- S-8 POSJul 1, 2022
- S-8 POSJul 1, 2022
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.